Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Olema Oncology (Nasdaq: OLMA) will present two preclinical posters at the AACR Annual Meeting in San Diego, April 17-22, 2026.

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) will present two preclinical posters at the AACR Annual Meeting in San Diego, April 17-22, 2026. Both presentations are scheduled on April 20, 2026 in the session "Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs."

Poster 2950 reports that palazestrant recruits corepressor NCoR1 leading to complete ERα antagonism; poster 2949 describes palazestrant plus OP-3136 synergistically downregulating proliferation and metastasis gene signatures.

Argus Mar 18 session

-3.25% close to close Open Argus

Details

News Market Reaction – OLMA

On Mar 18, the first trading day after this news, OLMA closed 3.25% below the previous close.

Data tracked by StockTitan Argus for the Mar 18 session.

Key Figures

AACR meeting dates: April 17–22, 2026 Palazestrant poster time: April 20, 2026, 2:00–5:00pm PT Combination poster time: April 20, 2026, 2:00–5:00pm PT +2 more

AACR meeting dates

April 17–22, 2026

American Association for Cancer Research Annual Meeting schedule

Palazestrant poster time

April 20, 2026, 2:00–5:00pm PT

Palazestrant NCoR1 recruitment preclinical poster session

Combination poster time

April 20, 2026, 2:00–5:00pm PT

Palazestrant + OP-3136 combination preclinical poster session

Palazestrant abstract ID

2950

Poster/abstract number for Palazestrant corepressor/NCoR1 study

Combination abstract ID

2949

Poster/abstract number for Palazestrant + OP-3136 combination study

Historical Context

5 past events · Latest: Mar 16

5 events

1. Mar 16

   Earnings & pipeline

   24h Move

   +9.6%

   Q4/FY 2025 results, $218.5M raise, $505.4M cash and late-stage pipeline progress.

2. Mar 03

   Inducement grants

   24h Move

   +3.9%

   Inducement stock options for four new employees under Nasdaq Listing Rule 5635(c)(4).

3. Feb 19

   Conference presentation

   24h Move

   +1.1%

   Announcement of CEO presentation at TD Cowen 46th Annual Health Care Conference.

4. Feb 04

   Investor conferences

   24h Move

   -5.0%

   Participation in three February 2026 investor conferences and related webcasts.

5. Feb 03

   Inducement grants

   24h Move

   +0.8%

   Inducement options for two new employees totaling 24,000 shares under 2022 plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

preclinical, corepressor, ncor1, estrogen receptor alpha, +3 more

7 terms

preclinical medical

"announced it will present two preclinical posters at the American Association for Cancer Research"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

corepressor medical

"Palazestrant directly recruits the corepressor protein NCoR1 in vitro"

A corepressor is a protein that helps shut down specific genes by joining with gene-controlling molecules and changing how tightly DNA is packaged—think of it as a clamp that keeps a switch turned off so the cell makes less of a particular product. For investors, corepressors matter because they are often drug targets or biomarkers in biotech: modulating them can determine a therapy’s effectiveness, selectivity, and potential side effects, which affects clinical outcomes and company value.

ncor1 medical

"directly recruits the corepressor protein NCoR1 in vitro leading to complete"

NCOR1 is a human gene that makes a protein which helps turn down or silence other genes, acting like a dimmer switch for the cell’s activity. Investors care because changes in NCOR1 function can drive or prevent disease and therefore influence the value of drugs, diagnostics, or therapies that target related pathways; evidence about NCOR1 can alter clinical prospects, regulatory decisions, and a company’s pipeline valuation.

estrogen receptor alpha medical

"leading to complete antagonism of estrogen receptor alphaPoster/Abstract: 2950"

Estrogen receptor alpha is a protein inside certain cells that binds the hormone estrogen and then activates or represses genes that control cell growth, survival and behavior. For investors, it matters because the receptor often determines whether a therapy or diagnostic will work: drugs that target it, tests that measure it, or changes in its activity can shape clinical trial results, regulatory approval chances and the commercial value of medical products—like a light switch that affects treatment outcomes.

kat6 inhibitor medical

"Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically"

A KAT6 inhibitor is a type of drug that blocks the activity of the KAT6 enzyme, which helps turn certain genes on by adding chemical tags; think of it as dimming a light switch that controls gene programs. Investors care because these inhibitors are being tested as treatments for cancers and other diseases, and clinical progress, safety results, or regulatory decisions can materially affect a company’s future revenue prospects and stock value.

metastasis medical

"synergistically downregulates cell proliferation and metastasis related gene signatures"

Metastasis is the process by which cancer cells break away from a primary tumor and travel to other parts of the body, where they form new tumors — like seeds carried by wind taking root in distant soil. It matters to investors because metastatic disease often requires more complex, longer-term treatments, drives larger market demand for advanced therapies, and strongly influences clinical trial design, regulatory decisions, and a drug’s commercial value.

american association for cancer research medical

"two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting"

A leading professional organization that supports and promotes cancer research by funding studies, publishing scientific journals and hosting conferences where researchers share new findings. Think of it as a central marketplace for scientific news: companies and labs present data and early results there, and those disclosures can change expectations about a drug’s chances or spark partnerships. Investors monitor its meetings and publications because new positive findings or collaborations announced through the group can move biotech and pharmaceutical stock values.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California.

Poster Presentation Details
Title: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha
Poster/Abstract: 2950
Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs
Date/Time: April 20, 2026, from 2:00-5:00pm PT / 5:00pm-8:00pm ET

Title: Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures
Poster/Abstract: 2949
Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs
Date/Time: April 20, 2026, from 2:00pm-5:00pm PT / 5:00pm-8:00pm ET

Additional information can be found on the AACR Annual Meeting website.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

About Palazestrant (OP-1250)
Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01, and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.

About OP-3136
OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical study.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “believe,” “could,” “expect,” “goal,” “intend,” “may,” “on track,” “potential,” “upcoming,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential beneficial characteristics including but not limited to safety, tolerability, activity, efficacy and therapeutic effects of palazestrant or OP-3136, the combinability of palazestrant or OP-3136 with other drugs, including in the metastatic setting, and the timelines for enrollment for current clinical studies and for the receipt and presentation of results of clinical trials of palazestrant and OP-3136 each as a monotherapy and in combination trials. Because such statements deal with future events and are based on Olema’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled “Risk Factors” in Olema’s Annual Report on Form 10-K for the year ended December 31, 2025, and future filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Olema (OLMA) present at the AACR Annual Meeting in 2026?

Olema will present two preclinical posters on April 20, 2026. According to the company, both posters appear in the session "Experimental and Molecular Therapeutics" and are scheduled from 2:00-5:00pm PT (5:00-8:00pm ET).

What does Olema's poster 2950 say about palazestrant (OLMA)?

Poster 2950 reports that palazestrant directly recruits NCoR1 and achieves complete ERα antagonism. According to the company, this is an in vitro preclinical finding highlighting palazestrant's corepressor recruitment mechanism in breast cancer models.

What is the focus of Olema's poster 2949 on palazestrant and OP-3136?

Poster 2949 shows that palazestrant plus OP-3136 synergistically downregulate proliferation and metastasis gene signatures. According to the company, the data describe preclinical combination effects involving a CERAN and a KAT6 inhibitor in cell models.

Where can investors find Olema (OLMA) AACR presentation details and timing?

Presentation details and timing are available on the AACR Annual Meeting program and website. According to the company, the two Olema posters are listed as abstracts 2949 and 2950 with session and time information for April 20, 2026.